166 related articles for article (PubMed ID: 9832347)
1. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Ulrich S; Neuhof S; Braun V; Meyer FP
Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
5. Serum haloperidol concentrations and clinical response in acute psychosis.
Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
[TBL] [Abstract][Full Text] [Related]
6. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.
Ulrich S; Wurthmann C; Brosz M; Meyer FP
Clin Pharmacokinet; 1998 Mar; 34(3):227-63. PubMed ID: 9533984
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.
Gerlach M; Hünnerkopf R; Rothenhöfer S; Libal G; Burger R; Clement HW; Fegert JM; Wewetzer Ch; Mehler-Wex C
Pharmacopsychiatry; 2007 Mar; 40(2):72-6. PubMed ID: 17447177
[TBL] [Abstract][Full Text] [Related]
9. Utility of neuroleptic blood levels in the treatment of acute psychosis.
Zohar J; Shemesh Z; Belmaker RH
J Clin Psychiatry; 1986 Dec; 47(12):600-3. PubMed ID: 3782046
[TBL] [Abstract][Full Text] [Related]
10. The relationship of haloperidol concentrations to therapeutic response.
Perry PJ; Pfohl BM; Kelly MW
J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Ulrich S; Sandmann U; Genz A
Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
[TBL] [Abstract][Full Text] [Related]
12. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
[TBL] [Abstract][Full Text] [Related]
13. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
14. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
15. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Stevens A; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
Odou P; Vaiva G; Luyckx M; Brunet C; Dine T; Gressier B; Cazin M; Cazin JC
Eur J Clin Pharmacol; 1996; 50(5):357-63. PubMed ID: 8839656
[TBL] [Abstract][Full Text] [Related]
18. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment.
Giegling I; Drago A; Schäfer M; Möller HJ; Rujescu D; Serretti A
J Psychiatr Res; 2010 Jun; 44(8):487-92. PubMed ID: 19962159
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: a therapeutic window relationship.
Ulrich S; Northoff G; Wurthmann C; Partscht G; Pester U; Herscu H; Meyer FP
Pharmacopsychiatry; 2001 Jan; 34(1):33-40. PubMed ID: 11229620
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis.
de Oliveira IR; de Sena EP; Pereira EL; Miranda AM; de Oliveira NF; Ribeiro MG; de Castro-e-Silva E; Dardennes RM; Samuel-Lajeunesse B; Marcilio C
J Clin Pharm Ther; 1996 Aug; 21(4):229-36. PubMed ID: 8933296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]